Suspension of trading
Cerevel Therapeutics Holdings, Inc. Share Price
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.96 USD | +0.74% |
|
-.--% | - |
| Market Cap | 819.15Cr 715.85Cr 660.57Cr 608.88Cr 1.15TCr 79TCr 1.17TCr 7.9TCr 3.11TCr 39TCr 3.08TCr 3.01TCr 1,33000Cr | P/E 2022 |
-13.6x | P/E 2023 | -15.9x |
|---|---|---|---|---|---|
| Enterprise Value | 749.61Cr 655.08Cr 604.49Cr 557.19Cr 1.05TCr 72TCr 1.07TCr 7.23TCr 2.84TCr 35TCr 2.82TCr 2.75TCr 1,21700Cr | EV / Sales 2022 |
-
| EV / Sales 2023 | - |
| Free-Float |
93.64% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +0.74% |
| 3 years | 19.59 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/05/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Scott Akamine
LAW | General Counsel | 42 | 24/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 20/01/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01/08/24 | Issuer sale | Director | 93,932 | 0.0516% | ||
| 01/08/24 | Issuer sale | Head of Human Resources | 8,00,774 | 0.4395% | ||
| 01/08/24 | Issuer sale | Director | 1,51,795 | 0.0833% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | -.--% | +53.66% | 819.15Cr | |
| +0.24% | -1.54% | +52.85% | +71.85% | 5.38TCr | |
| -7.17% | -4.39% | +42.72% | +73.32% | 5.21TCr | |
| +0.80% | -6.31% | +5.62% | +417.78% | 2.35TCr | |
| -0.09% | -0.01% | -16.85% | -15.41% | 2.31TCr | |
| -5.95% | -2.58% | +29.53% | -9.47% | 1.94TCr | |
| -1.14% | +0.03% | +31.67% | -30.65% | 1.76TCr | |
| -5.16% | -7.00% | +168.44% | +314.96% | 1.52TCr | |
| -6.91% | -5.83% | +25.17% | +644.30% | 1.48TCr | |
| +0.43% | -1.03% | +25.75% | +189.74% | 1.41TCr | |
| Average | -2.42% | -2.36% | +36.49% | +171.01% | 2.42TCr | |
| Weighted average by Cap. | -2.68% | -2.28% | +38.21% | +140.10% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | - | - |
| Net income | -35Cr -31Cr -28Cr -26Cr -49Cr -3.39TCr -50Cr -338.81Cr -133.26Cr -1.66TCr -132.01Cr -129.11Cr -5.71TCr | -43Cr -38Cr -35Cr -32Cr -61Cr -4.17TCr -62Cr -417.2Cr -164.09Cr -2.04TCr -162.55Cr -158.99Cr -7.03TCr |
| Net Debt | -52Cr -46Cr -42Cr -39Cr -73Cr -5.04TCr -75Cr -504.33Cr -198.36Cr -2.47TCr -196.5Cr -192.19Cr -8.5TCr | -70Cr -61Cr -56Cr -52Cr -97Cr -6.7TCr -100Cr -670.26Cr -263.63Cr -3.28TCr -261.15Cr -255.42Cr -11TCr |
Employees
355
- Stock Market
- Stocks
- CERE Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
